Mediation and moderation of treatment effects in randomised controlled trials of complex interventions

Statistical Methods in Medical Research

Volumn 19, Issue 3, 2010, Pages 237-270

  Emsley, Richard ^a   Dunn, Graham ^a   White, Ian R ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MRC BIOSTATISTICS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; COGNITIVE THERAPY; COUNSELING; INTERVENTION STUDY; MENTAL HEALTH; METHODOLOGY; PARAMETER; REVIEW; STATISTICAL ANALYSIS; STRATIFICATION; TREATMENT OUTCOME; BIOSTATISTICS; DEPRESSION; HUMAN; OUTCOME ASSESSMENT; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SCHIZOPHRENIA; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; SUICIDE;

BIOSTATISTICS; DEPRESSION; HUMANS; MENTAL HEALTH; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK REDUCTION BEHAVIOR; SCHIZOPHRENIA; SUICIDE; TREATMENT OUTCOME;

EID: 77954416860     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1177/0962280209105014     Document Type: Review

References (111)

1. Kraemer HC, Wilson GT, Fairburn CG, Agras WS Mediators and moderators of treatment effects in randomised clinical trials. Archives of General Psychiatry 2002; 59 (10). 877-883.
2. Kazdin AE, Nock MK Delineating mechanisms of change in child and adolescent therapy: methodological issues and research recommendations. The Journal of Child Psychology and Psychiatry 2003; 44 (8). 1116-1129.
3. Oakley A., Strange V., Bonell C., Allen E., Stephenson J. Process evaluation in randomised controlled trials of complex interventions. British Medical Journal 2006; 332 (7538). 413-416.
4. Green J., Dunn G. Using intervention trials in developmental psychiatry to illuminate basic science. British Journal of Psychiatry 2008; 192 (5). 323-325.
5. Baron RM, Kenny DA The moderator-mediator variable distinction in social pychological research: conceptual, strategic, and statistical considerations. Journal of Personality and Social Psychology 1986; 51: 1173-1182.
6. Bruce ML, Ten Have TR, Reynolds CF et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients-a randomised controlled trial. Journal of the American Medical Association 2004; 291 (9). 1081-1091.
7. Lewis S., Tarrier N., Haddock G. et al. Randomised controlled trial of cognitive-behavioural therapy in early schizophrenia: acute-phase outcomes. British Journal of Psychiatry 2002; 181: S91-7.
8. Pearl J. Causality (1 st edn). Cambridge University Press, New York, 2000.
9. Ten Have TR, Joffe MM, Lynch KG, Brown GK, Maisto SA, Beck AT Causal mediation analyses with rank preserving models. Biometrics 2007; 63 (3). 926-934.
10. Bellamy SL, Lin JY, Ten Have TR An introduction to causal modelling in clinical trials. Clinical Trials 2007; 4 (1). 58-73.
11. Lynch K., Cary M., Gallop R., Ten Have TR Causal mediation analyses for randomised trials. Health Services and Outcomes Research Methodology 2008; 8: 57-76.
12. Gallop R., Small DS, Lin JY, Elliot MR, Joffe M.M., Ten Have T.R. Mediation analysis with principal stratification. Statistics in Medicine 2009; 28 (7). 1108-1130.
13. Hamilton M. A rating scale for depression. Journal of Neurology Neurosurgery and Psychiatry 1960; 23 (1). 56-62.
14. Beck AT, Brown GK, Steer RA Psychometric characteristics of the scale for suicide ideation with psychiatric outpatients. Behaviour Research and Therapy 1997; 35 (11). 1039-1046.
15. Tarrier N., Lewis S., Haddock G. et al. Cognitive-behavioural therapy in first-episode and early schizophrenia-18-month follow-up of a randomised controlled trial. British Journal of Psychiatry 2004; 184: 231-239.
16. Green J. Annotation: the therapeutic alliance-a significant but neglected variable in child mental health treatment studies. The Journal of Child Psychology and Psychiatry 2006; 47 (5). 425-435.
17. Gunderson JG, Frank AF, Katz HM, Vannicelli ML, Frosch JP, Knapp PH Effects of psychotherapy in schizophrenia: II. Comparative outcome of two forms of treatment. Schizopreria Bulletin 1984; 10 (4). 564-598.
18. Kay SR, Fiszbein A., Opler LA The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987; 13 (2). 261-276.
19. Dunn G., Bentall R. Modelling treatment-effect heterogeneity in randomised controlled trials of complex interventions (psychological treatments). Statistics in Medicine 2007; 26 (26). 4719-4745.
20. Wright S. Correlation and causation. Journal of Agricultural Research 1921; 20: 557-585.
21. Wright S. The method of path coefficients. Annals of Mathematical Statistics 1934; 5: 161-215.
22. Simon HA Spurious correlation: A causal interpretation. Journal of the American Statistical Association 1954; 49: 467-479.
23. Duncan OD Path analysis-sociological examples. American Journal of Sociology 1966; 72 (1). 1-16.
24. Blalock HM Causal models in the social sciences. Aldine-Atherton, Chicago, 2008.
25. Goldberg AS Structural equation methods in social sciences. Econometrica 1972; 40 (6). 979-1001.
26. Bollen K. Structural equations with latent variables (2 nd edn). John Wiley and Sons, Inc, New York, 1989.
27. Rubin DB Estimating causal effects of treatment in randomised and non-randomised studies. Journal of Educational Psychology 1974; 66: 688-701.
28. Rubin DB Causal inference using potential outcomes: Design, modeling, decisions. Journal of the American Statistical Association 2005; 100 (469). 322-331.
29. Heckman J. Sample selection bias as a specification error. Econometrica 1979; 47 (1). 153-161.
30. Heckman J. Varieties of selection bias. American Economic Review 1990; 80 (2). 313-318.
31. Heckman JJ Econometric causality. International Statistical Review 2008; 76 (1). 1-27.
32. Holland PW Statistics and causal inference. Journal of the American Statistical Association 1986; 81 (396). 945-960.
33. Holland PW Causal inference, path analysis and recursive structural equation models (with discussion). Sociological Methodology 1988; 18: 449-484.
34. Robins JM A new approach to causal inference in mortality studies with a sustained exposure period-application to control of the healthy worker survivor effect. Mathematical Modelling 1986; 7 (9-12). 1393-1512.
35. MacKinnon DP Introduction to statistical mediation analysis (1st edn). Taylor and Francis Group, New York, 2008.
36. MacKinnon DP, Dwyer JH Estimating mediated effects in prevention studies. Evaluation Review 1993; 17 (2). 144-158.
37. Judd CM, Kenny DA Process analysis-estimating mediation in treatment evaluations. Evaluation Review 1981; 5 (5). 602-619.
38. Robins JM, Greenland S. Identifiability and exchangeability for direct and indirect effects. Epidemiology 1992; 3 (2). 143-155.
39. Ten Have TR, Elliott MR, Joffe M., Zanutto E., Datto C. Causal models for randomised physician encouragement trials in treating primary care depression. Journal of the American Statistical Association 2004; 99 (465). 16-25.
40. Joffe MM, Small D., Hsu CY Defining and estimating intervention effects for groups that will develop an auxiliary outcome. Statistical Science 2007; 22 (1). 74-97.
41. Herting JR Evaluating and rejecting true mediation models: A cautionary note. Prevention Science 2002; 3 (4). 285-289.
42. Kaufman JS, MacLehose R., Kaufman S. A further critique of the analytic strategy of adjusting for covariates to identify biologic mediation. Epidemiologic Perspectives and Innovations 2004; 1 (4).
43. Kaufman S., Kaufman JS, MacLehose RF, Greenland S., Poole C. Improved estimation of controlled direct effects in the presence of unmeasured confounding of intermediate variables. Statistics in Medicine 2005; 24: 1683-1702.
44. Tritchler D. Explanatory analyses of randomised studies. Biometrics 1996; 52 (4). 1450-1456.
45. Tritchler D. Reasoning about data with directed graphs. Statistics in Medicine 1999; 18 (16). 2067-2076.
46. McDonald RP Haldane's lungs: A case study in path analysis. Multivariate Behavioral Research 1997; 32 (1). 1-38.
47. Pearl J. Direct and indirect effects. In Proceedings of the seventeenth conference on uncertainty in artificial intelligence. 2001; 411-420.
48. Cai ZH, Kuroki M., Pearl J., Tian J. Bounds on direct effects in the presence of confounded intermediate variables. Biometrics 2008; 64 (3). 695-701.
49. Robins JM Semantics of causal DAG models and the identification of direct and indirect effects. In Green P, Hjort N, Richardson S, eds. Highly structured stochastic systems. Oxford University Press, New York, 2003: 70-81.
50. Rubin DB Direct and indirect causal effects via potential outcomes. Scandinavian Journal of Statistics 2004; 31 (2). 161-170.
51. Lauritzen SL Discussion on causality. Scandinavian Journal of Statistics 2004; 31 (2). 189-192.
52. Petersen ML, Sinisi SE, van der Laan MJ Estimation of direct causal effects. Epidemiology 2006; 17 (3). 276-284.
53. Geneletti S. Identifying direct and indirect effects in a non-counterfactual framework. Journal of the Royal Statistical Society Series B-Statistical Methodology 2007; 69: 199-215.
54. Goetgeluk S., Vansteelandt S., Goetghebeur E. Estimation of controlled direct effects. Journal of the Royal Statistical Society Series B-Statistical Methodology 2008; 70: 1049-1066.
55. Wooldridge JM Introductory econometrics: A modern approach (2nd edn). Thompson Learning, USA, 2003.
56. Permutt T., Hebel JR Simultaneous-equation estimation in a clinical-trial of the effect of smoking on birth-weight. Biometrics 1989; 45 (2). 619-622.
57. Bloom HS Accounting for no-shows in experimental evaluation designs. Evaluation Review 1984; 8 (2). 225-246.
58. Newcombe RG Explanatory and pragmatic estimates of the treatment effect when deviations from allocated treatment occur. Statistics in Medicine 1988; 7 (11). 1179-1186.
59. Sommer A., Zeger SL On estimating efficacy from clinical-trials. Statistics in Medicine 1991; 10 (1). 45-52.
60. Follmann DA On the effect of treatment among would-be treatment compliers: An analysis of the multiple risk factor intervention trial. Journal of the American Statistical Association 2000; 95 (452). 1101-1109.
61. Imbens GW, Angrist JD Identification and estimation of local average treatment effects. Econometrica 1994; 62 (2). 467-475.
62. Angrist JD, Imbens GW, Rubin DB Identification of causal effects using instrumental variables. Journal of the American Statistical Association 1996; 91 (434). 444-455.
63. Baker SG, Lindeman KS The paired availability design-a proposal for evaluating epidural analgesia during labor. Statistics in Medicine 1994; 13 (21). 2269-2278.
64. Frangakis CE, Rubin DB Principal stratification in causal inference. Biometrics 2002; 58 (1). 21-29.
65. White IR Uses and limitations of randomization-based efficacy estimators. Statistical Methods in Medical Research 2005; 14 (4). 327-347.
66. Baker SG, Kramer BS Simple maximum likelihood estimates of efficacy in randomised trials and before-and-after studies, with implications for meta-analysis. Statistical Methods in Medical Research 2005; 14 (4). 349-367.
67. Dunn G., Maracy M., Tomenson B. Estimating treatment effects from randomised clinical trials with noncompliance and loss to follow-up: The role of instrumental variable methods. Statistical Methods in Medical Research 2005; 14 (4). 369-395.
68. Li F., Frangakis CE Designs in partially controlled studies: Messages from a review. Statistical Methods in Medical Research 2005; 14 (4). 417-431.
69. Angrist JD, Imbens GW 2-stage least-squares estimation of average causal effects in models with variable treatment intensity. Journal of the American Statistical Association 1995; 90 (430). 431-442.
70. Robins JM Correcting for non-compliance in randomised trials using structural nested mean models. Communications in Statistics-Theory and Methods 1994; 23 (8). 2379-2412.
71. Goetghebeur E., Lapp K. The effect of treatment compliance in a placebo-controlled trial: Regression with unpaired data. Applied Statistics-Journal of the Royal Statistical Society Series C 1997; 46 (3). 351-364.
72. Fischer-Lapp K., Goetghebeur E. Practical properties of some structural mean analyses of the effect of compliance in randomised trials. Controlled Clinical Trials 1999; 20 (6). 531-546.
73. Goetghebeur E., Vansteelandt S. Structural mean models for compliance analysis in randomised clinical trials and the impact of errors on measures of exposure. Statistical Methods in Medical Research 2005; 14 (4). 397-415.
74. Maracy M., Dunn G. Estimating dose-response effects in psychological treatment trials: The role of instrumental variables. Statistical Methods in Medical Research 2008; (In press).
75. Fischer K., Goetghebeur E. Structural mean effects of noncompliance: estimating interaction with baseline prognosis and selection effects. Journal of the American Statistical Association 2004; 99 (468). 918-928.
76. Gennetian LA, Morris PA, Bos JM, Bloom HS Constructing instrumental variables from experimental data to explore how treatments produce effects. In Bloom HS, ed. Learning more from social experiments: evolving analytic approaches (1st edn). Russell Sage Foundation, New York, 2005: 75-114.
77. Gennetian LA, Magnuson K., Morris PA From statistical associations to causation: What developmentalists can learn from instrumental variables techniques coupled with experimental data. Developmental Psychology 2008; 44 (2). 381-394.
78. Sobel ME Identification of causal parameters in randomised studies with mediating variables. Journal of Educational and Behavioral Statistics 2008; 33 (2). 230-251.
79. Albert JM Mediation analysis via potential outcomes models. Statistics in Medicine 2008; 27 (8). 1282-1304.
80. Jo B. Causal inference in randomised experiments with mediational processes. Psychological Methods 2008; 13 (4). 314-336.
81. Prentice RL Surrogate endpoints in clinical-trials-definition and operational criteria. Statistics in Medicine 1989; 8 (4). 431-440.
82. Weir CJ, Walley RJ Statistical evaluation of biomarkers as surrogate endpoints: A literature review. Statistics in Medicine 2006; 25 (2). 183-203.
83. Joffe M.M., Greene T. Related causal frameworks for surrogate outcomes. Biometrics 2008; (In press).
84. Aguinis H. Regression analysis for categorical moderators. Guilford, New York, 2004.
85. Aitken LS, West SG Multiple regression: Testing and interpreting interactions. SAGE, Newbury Park, 1991.
86. Heckman J., Vytlacil E. Instrumental variables methods for the correlated random coefficient model-estimating the average rate of return to schooling when the return is correlated with schooling. Journal of Human Resources 1998; 33 (4). 974-987.
87. Heckman JJ, Urzua S., Vytlacil E. Understanding instrumental variables in models with essential heterogeneity. Review of Economics and Statistics 2006; 88 (3). 389-432.
88. Wooldridge JM On two stage least squares estimation of the average treatment effect in a random coefficient model. Economics Letters 1997; 56 (2). 129-133.
89. Wooldridge JM Further results on instrumental variables estimation of average treatment effects in the correlated random coefficient model. Economics Letters 2003; 79 (2). 185-191.
90. Mealli F., Rubin DB Commentary-Assumptions allowing the estimation of direct causal effects. Journal of Econometrics 2003; 112 (1). 79-87.
91. Daniels MJ, Hughes MD Meta-analysis for the evaluation of potential surrogate markers. Statistics in Medicine 1997; 16 (17). 1965-1982.
92. Burzykowski T., Molenberghs G., Buyse M. The evaluation of surrogate endpoints. Springer, New York, 2006.
93. Intercooled Stata Statistical Software: Release 10.0 [computer program]. Stata Corporation, College Station, TX; 2007.
94. Florens JP, Heckman JJ, Meghir C., Vytlacil E. Identification of treatment effects using control functions in models with continuous, endogenous treatment and heterogeneous effects. Econometrica 2008; 76 (5). 1191-1206.
95. Robins JM, Greenland S. Adjusting for differential rates of prophylaxis therapy for PCP in high-dose versus low-dose AZT treatment arms in an AIDS randomised trial. Journal of the American Statistical Association 1994; 89 (427). 737-749.
96. Jo B. Estimation of intervention effects with noncompliance: alternative model specifications. Journal of Educational and Behavioral Statistics 2002; 27 (4). 385-409.
97. Imbens GW, Rubin DB Bayesian inference for causal effects in randomised experiments with noncompliance. Annals of Statistics 1997; 25 (1). 305-327.
98. Imbens GW, Rubin DB Estimating outcome distributions for compliers in instrumental variables models. Review of Economic Studies 1997; 64 (4). 555-574.
99. Little RJ, Yau LHY. Statistical techniques for analyzing data from prevention trials: treatment of no-shows using Rubin's causal model. Psychological Methods 1998; 3 (2). 147-159.
100. Jo B., Muthén BO Modeling of intervention effects with noncompliance: a latent variable approach for randomised trials. In Marcoulides GA, Schumacker RE, eds. New developments and techniques in structural equation modeling. Lawrence Erlbaum Associates, Mahwah, New Jersey, 2001: 57-87.
101. Jo B., Muthén BO Longitudinal studies with intervention and noncompliance: estimation of causal effects in growth mixture modeling. In Duan N, Reise S, eds. Multilevel modeling: methodological advances, issues, and applications. Lawrence Erlbaum Associates, Mahwah, NJ, 2002: 112-139.
102. Yau LHY, Little RJ Inference for the complier-average causal effect from longitudinal data subject to noncompliance and missing data, with application to a job training assessment for the unemployed. Journal of the American Statistical Association 2001; 96 (456). 1232-1244.
103. Peng YH, Little RJA, Raghunathan TE An extended general location model for causal inferences from data subject to noncompliance and missing values. Biometrics 2004; 60 (3). 598-607.
104. Mealli F., Imbens GW, Ferro S., Biggeri A. Analyzing a randomised trial on breast self-examination with noncompliance and missing outcomes. Biostatistics 2004; 5 (2). 207-222.
105. Croudace T., Dunn G., Pickles A. General latent variable modelling using mplus. Chapman and Hall, London, 2010.
106. Muthén LK, Muthén BO Mplus user's guide. Muthén and Muthén, Los Angeles, CA, 1998.
107. Frangakis CE, Rubin DB Addressing complications of intention-to-treat analysis in the combined presence of all-or-none treatment-noncompliance and subsequent missing outcomes. Biometrika 1999; 86 (2). 365-379.
108. Pickles A., Croudace T. Latent mixture models for multivariate and longitudinal outcomes. Statistical Methods in Medical Research 2010; 19 (3). 271-289.
109. Hausman JA Specification tests in econometrics. Econometrica 1978; 46 (6). 1251-1271.
110. Follmann D. Augmented designs to assess immune response in vaccine trials. Biometrics 2006; 62 (4). 1161-1169.
111. Robins JM Testing and estimation of direct effects by reparameterizing directed acyclic graphs with structural nested models. In Glymour C, Cooper G, eds. Computation, Causation, and Discovery. AAAI Press/ The MIT Press, Menlo Park, CA, Cambridge, MA, 1999: 349-405.